CLPT

$11.16

Post-MarketAs of Mar 17, 8:00 PM UTC

ClearPoint Neuro, Inc.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$11.16
Potential Upside
5%
Whystock Fair Value$11.72
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventi...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$331.99M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-103.13%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
5.40

Recent News

Motley Fool
Mar 17, 2026

ClearPoint Neuro (CLPT) Earnings Call Transcript

Joseph Burnett: Thank you. This is one of the largest unmet needs in all of medicine, and we at ClearPoint Neuro, Inc. believe we can play a crucial role in this exciting future. This foundation is made up of four growing product categories, a vetted pipeline of new development programs, an expanded manufacturing footprint, a thoroughly audited quality system, a collection of global regulatory approvals, an expansive IP portfolio, an installed base of more than 150 global centers, and the cash position and investor base to execute on our strategy.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 16, 2026

ClearPoint Neuro Inc (CLPT) Q4 2025 Earnings Report Preview: What To Expect

The consensus estimate for Q4 2025 revenue is $10.05 million, and the earnings are expected to come in at -$0.20 per share. The full year 2025's revenue is expected to be $36.60 million, and the earnings are expected to be -$0.83 per share. More detailed estimate data can be found on the Forecast page.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 9, 2026

ClearPoint Neuro (CLPT) Moves 8.1% Higher: Will This Strength Last?

ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 7, 2026

How The ClearPoint Neuro (CLPT) Investment Story Is Shifting After FDA Feedback And Valuation Cut

ClearPoint Neuro is back in focus after analysts cut their price target from US$28 to US$18, while also lowering their fair value estimate from US$29 to US$24. The move reflects a mix of optimism around more than 60 biopharma partners and six clinical stage intracranial programs, set against higher perceived risk following recent FDA feedback and related share price pressure. As you read on, you will see what is driving this evolving narrative and how to keep track of the moving...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Jan 27, 2026

CLPT Gets EU MDR Certification for ClearPoint Navigation Software

ClearPoint secures EU MDR certification for ClearPoint Navigation Software 3.0.2, expanding precision-guided surgery access across MRI suites and operating rooms.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.